At BIOMIMETICS SYMPATHIES, we provide a variety of technologies, know-how, products, and services related to regenerative medicine to companies in Japan and
overseas, as well as to universities and public research institutions. Please feel free to contact us if you wish to conduct joint research, to obtain products such as cell
culture media, or to require other business support.

We would like to work with individuals who share our vision and values.
Together, let’s pave the way for a better future for those suffering from illnesses.
Whether you can participate in the project a few days a month or are interested in consultancy contracts, we welcome you.

Services and support for companies

  • Provision of original
    MSC media

  • Licensing out our cell culture medium technology for regenerative medicine and intellectual property of development candidates.

  • Provision of raw materials for cosmetics based on regenerative medicine technology

  • Joint development of new technologies and products

Achievement of licensing out/technology transfer agreement

  • Joint research and development agreement on serum-free medium for mesenchymal stem cells

    Japanese pharmaceutical company in 2013

  • Technology transfer agreement for umbilical cord derived stem cell culture medium

    Singapore Bio Company in 2016

  • Licensing out of diagnostic technology for ovarian cancer stage (MMP1)

    to an undisclosed party in 2018

* In addition, we have track records, mainly in Japan and Asian countries including China, with multiple companies that wish to adopt our company’s regenerative medicine technology and of contract research and development agreements.

Joint research with universities and research institutions

We are currently conducting multiple joint research studies, mainly in evaluating pharmacology and developing highly functional MSC. We also accept requests for research reagents such as media that can produce stable results in basic research, exosomes, and cell culture supernatants.

Joint research experience

The University of Tokyo, Niigata University, Tohoku University, Kagoshima University, Shiga University of Medical Science, Fukuoka University, Waseda University, The University of Alabama (USA), National Cancer Center Research Institute, Juntendo University, Keio University, The University of Kitakyushu, Kyushu University, Monell Chemical Senses Center (USA)

* We also established a laboratory for industry-academia collaboration at Tokyo Medical University (April 2015 to March 2018).

* Insert list of articles.

List for joint research papersOPEN

Intra-Articular Injections of the Adipose-Derived Mesenchymal Stem Cells Suppress Progression of a Mouse Traumatic Knee Osteoarthritis Model.
Wakayama T, Saita Y, Nagao M, Uchino S, Yoshihara SI, Tsuji K, Koga H, Kobayashi Y, Nishio H, Momoi Y, Ikeda H, Kaneko K, Ishijima M.
Cartilage. 2022 Dec;13(4):148-156. doi: 10.1177/19476035221132262. Epub 2022 Oct 31.
Effect of human adipose-derived mesenchymal stem cell conditioned medium on musculoskeletal pain.
Sano M, Tanabe A, Urushihata N, Liu XL.
Eur Rev Med Pharmacol Sci. 2022 Mar;26(5):1570-1578. doi: 10.26355/eurrev_202203_28223.
Intravenous administration of human mesenchymal stem cells derived from adipose tissue and umbilical cord improves neuropathic pain via suppression of neuronal damage and anti-inflammatory actions in rats.
Miyano K, Ikehata M, Ohshima K, Yoshida Y, Nose Y, Yoshihara SI, Oki K, Shiraishi S, Uzu M, Nonaka M, Higami Y, Uezono Y.
PLoS One. 2022 Feb 14;17(2):e0262892. doi: 10.1371/journal.pone.0262892. eCollection 2022.
Anti-fibrotic effect of adipose-derived mesenchymal stem cell conditioned medium in muscle fibrosis.
Oki K, Yoshihara S, Urushihata N, Ghazizadeh M.
Eur Rev Med Pharmacol Sci. 2021 Aug;25(15):4953-4963. doi: 10.26355/eurrev_202108_26452.
Long-term survival of a patient with ALS who received autologous adipose-derived mesenchymal stem cells.
Shigematsu K, Takeda T, Komori N, Urushihata N, Oki K, Tahara K, Yamagishi H.
Eur Rev Med Pharmacol Sci. 2021 Jun;25(11):4086-4090. doi: 10.26355/eurrev_202106_26050
Exposure to small molecule cocktails allows induction of neural crest lineage cells from human adipose-derived mesenchymal stem cells.
Takayama Y, Akagi Y, Shibuya Y, Kida YS.
PLoS One. 2020 Oct 26;15(10):e0241125. doi: 10.1371/journal.pone.0241125. eCollection 2020.
Enhanced expression of synoviolin in peripheral blood from obese/overweight donors.
Fujita H, Aratani S, Mizoguchi I, Yagishita N, Nakajima T.
Exp Ther Med. 2020 Nov;20(5):121. doi: 10.3892/etm.2020.9249. Epub 2020 Sep 21.
Intranasal Administration of Conditioned Medium from Cultured Mesenchymal Stem Cells Improves Cognitive Impairment in Olfactory Bulbectomized Mice.
Kojima K, Kawahata I, Izumi H, Yoshihara S, Oki K, Fukunaga K.
Advances in Alzheimer’s Disease. 2020 Sep;9 (3):47-56. doi: 10.4236/aad.2020.93004.
Effects of Human Adipose Tissue-Derived and Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in a Dextran Sulfate Sodium-Induced Mouse Model.
Ikarashi S, Tsuchiya A, Kawata Y, Kojima Y, Watanabe T, Takeuchi S, Igarashi K, Ideta-Otsuka M, Oki K, Takamura M, Terai S.
Biores Open Access. 2019 Nov 11;8(1):185-199. doi: 10.1089/biores.2019.0022. eCollection 2019.
A new method to confirm the absence of human and animal serum in mesenchymal stem cell culture media.
Ota M, Takagaki K, Takaoka S, Tanemura H, Urushihata N.
Int J Med Sci. 2019 Aug 6;16(8):1102-1106. doi: 10.7150/ijms.32100. eCollection 2019.
Development and Validation of an Esophageal Squamous Cell Carcinoma Detection Model by Large-Scale MicroRNA Profiling.
Sudo K, Kato K, Matsuzaki J, Boku N, Abe S, Saito Y, Daiko H, Takizawa S, Aoki Y, Sakamoto H, Niida S, Takeshita F, Fukuda T, Ochiya T.
JAMA Netw Open. 2019 May 3;2(5):e194573. doi: 10.1001/jamanetworkopen.2019.4573.
Effect of the Aspect Ratio of Coiled-Coil Protein Carriers on Cellular Uptake.
Nakayama N, Takaoka S, Ota M, Takagaki K, Sano KI.
Langmuir. 2018 Nov 27;34(47):14286-14293. doi: 10.1021/acs.langmuir.8b02616. Epub 2018 Nov 12.
Assessment of safety and feasibility of human allogeneic adipose-derived mesenchymal stem cells in a pediatric patient.
Hirano A, Sano M, Urushihata N, Tanemura H, Oki K, Suzaki E.
Pediatr Res. 2018 Nov;84(5):575-577. doi: 10.1038/s41390-018-0042-8. Epub 2018 May 18.
Extracellular microRNAs and oxidative stress in liver injury: a systematic mini review.
Matsuzaki J, Ochiya T.
J Clin Biochem Nutr. 2018 Jul;63(1):6-11. doi: 10.3164/jcbn.17-123. Epub 2018 Apr 11.
Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer, Second Report.
Goto A, Noto H, Noda M, Ueki K, Kasuga M, Tajima N, Ohashi K, Sakai R, Tsugane S, Hamajima N, Tajima K, Imai K, Nakagama H.
Diabetol Int. 2016 Mar 7;7(1):12-15. doi: 10.1007/s13340-016-0257-z. eCollection 2016 Mar.
Adipose-Derived Mesenchymal Stem Cells Restore Impaired Mucosal Immune Responses in Aged Mice.
Aso K, Tsuruhara A, Takagaki K, Oki K, Ota M, Nose Y, Tanemura H, Urushihata N, Sasanuma J, Sano M, Hirano A, Aso R, McGhee JR, Fujihashi K.
PLoS One. 2016 Feb 3;11(2):e0148185. doi: 10.1371/journal.pone.0148185. eCollection 2016.
Potential Application of Extracellular Vesicles of Human Adipose Tissue-Derived Mesenchymal Stem Cells in Alzheimer’s Disease Therapeutics..
Katsuda, T., Oki, K., Ochiya, T.
Methods Mol Biol. 2015;1212:171-81. doi: 10.1007/7651_2014_98.
A Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.
Katsuda T, Tsuchiya R, Kosaka N, Yoshioka Y, Takagaki K, Oki K, Takeshita F, Sakai Y, Kuroda M, Ochiya T.
Sci Rep. 2013;3:1197. doi: 10.1038/srep01197.

Discussions by leading expert on the current and
future of regenerative medicine

YASUSHI SAITO

Yasushi Saito

Special Advisor, Future Medicine Education and Research Organization at Chiba University

We must say that the overall image of how the power of cells to “cure diseases” is brought out is still unknown. For this reason, the “cure of diseases” is approached not only from the field of medicine but also from many fields. I encountered an opportunity to learn about sick individuals overcoming diseases. I also learned about approaching diseases by teaching cells to attack them. I hope to enhance that joy through this new healthcare option. - I want to learn about “the cure of diseases” from many cases.

【Profile】
1968s Niigata University, Faculty of Medicine Hospital Clinical resident
1972s Tokushima University, Enzyme Research Institute, Department of enzyme physiology
1975s Chiba University, School of Medicine, Second Department of Internal Medicine Assistant professor
1984s Chiba University, School of Medicine, Second Department of Internal Medicine Lecturer
1993s Yamagata University, Faculty of Medicine, Department of Clinical Laboratory Medicine Professor
1995s Chiba University, School of Medicine, Second Department of Internal MedicineProfessor
2001s Chiba University, Graduate School of Medicine, Department of Cell Therapy President of the Hospital
2005s Chiba University Hospital (also Cell Therapy Professor)Hospital Director
2007s Chiba University (also Cell Therapy Professor)Executive Director, Vice President
2008s Chiba University President
2014s Chiba City Hospital Executive Managing Director
2021s Future Medicine Education and Research Organization at Chiba University Directorr Special Advisor
【Main focus of research】
Development of the treatment for enzyme deficiency disorders using adipocytes with regenerative medical methods Hypocholesterolemic drug; the invention and clinical development of a new statin, LIVALO.
【Awards】
The Order of the Sacred Treasure, Gold and Silver Star
Award from the Japan Atherosclerosis Society
Award from Japan Society for the Study of Obesity
Excellent paper award from Diabetologia
Distinguished researcher Award
Profile